- Home
- ILLR vs STTK Comparison
ILLR vs STTK Comparison
Compare ILLR & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ILLR | STTK |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.5M | 119.0M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ILLR | STTK |
|---|---|---|
| Price | $0.76 | $2.86 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 785.5K | 328.1K |
| Earning Date | 12-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $45,244,000.00 | $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.33 | $0.69 |
| 52 Week High | $3.15 | $3.38 |
Technical Indicators
Market Signals| Indicator | ILLR | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 67.74 | 63.56 |
| Support Level | $0.51 | $1.93 |
| Resistance Level | $0.80 | $3.30 |
| Average True Range (ATR) | 0.08 | 0.24 |
| MACD | 0.05 | 0.06 |
| Stochastic Oscillator | 92.27 | 69.31 |
Price Performance
Historical ComparisonAbout ILLR Triller Group Inc.
Triller Group Inc is a us-based company that operates its businesses through Triller Corp which operates as a technology platform and AGBA Group Holding Limited operates as an insurance and wealth distribution platform.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.